抗肝纤维化药物的研究进展  

Research Progression of Anti-hepatic Fibrosis Drugs

作　　者：薛青山[1] 左长京[2] 王霆[1,3] 

机构地区：[1]中南大学药学院,湖南长沙410013 [2]第二军医大学长海医院核医学科,上海200433 [3]广州威尔曼新药研发有限公司,广东广州510075

出　　处：《中药新药与临床药理》2013年第6期633-638,共6页Traditional Chinese Drug Research and Clinical Pharmacology

基　　金：广州市重大科技计划专项(2009A1-E011-4)

摘　　要：综述近年来抗肝纤维化药物研究的概况。肝纤维化是持续的慢性损害所致的肝脏细胞外基质(ECM)过度沉积和组织结构重构的病理变化,肝星状细胞(HSCs)的活化为其发生的关键环节。不断阐明的肝纤维化分子机制使抗肝纤维化药物研究有了长足进步。目前,抗肝纤维化药物主要包括肝细胞保护剂、ECM合成降解调节剂、HSCs活化凋亡调节剂、抗炎免疫调节剂。中医药治疗肝纤维化研究也取得了一定的进展。This recent progress in the research of anti-fibrotic drugs in recent years was reviewed. Hepatic fibrosis, resulted from sustained chronic liver injuries, is a pathological change characterized by the excessive accumulation of extracellular matrix （ECM） including collagen and other ECM components and characterized by the tissue structure reconstruction, in which the activation of hepatic stellate cells（HSCs） plays a pivotal role. Continuous clarification of molecular mechanisms has witnessed tremendous progress in the research and development of hepatic anti-fibrotic drugs covering hepatocyte protective agent, ECM synthesis and degradation modulator, HSCs activation and apoptosis modulator, anti-imqammatory agent and imnmnomodulator, and traditional Chinese medicine in treating hepatic fibrosis has also achieved some progress.

关 键 词：肝纤维化 分子机制 药物靶点 

分 类 号：R96[医药卫生—药理学] R285.5[医药卫生—药学]